Goldstream Capital Management Ltd Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

Goldstream Capital Management Ltd lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 190.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,685 shares of the company’s stock after acquiring an additional 3,729 shares during the period. Eli Lilly and Company accounts for about 2.2% of Goldstream Capital Management Ltd’s holdings, making the stock its 15th biggest position. Goldstream Capital Management Ltd’s holdings in Eli Lilly and Company were worth $3,314,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of LLY. Buckhead Capital Management LLC grew its position in Eli Lilly and Company by 0.7% in the 4th quarter. Buckhead Capital Management LLC now owns 2,104 shares of the company’s stock valued at $1,226,000 after buying an additional 15 shares during the last quarter. Levin Capital Strategies L.P. grew its position in Eli Lilly and Company by 3.8% in the 4th quarter. Levin Capital Strategies L.P. now owns 415 shares of the company’s stock valued at $242,000 after buying an additional 15 shares during the last quarter. JGP Wealth Management LLC grew its position in Eli Lilly and Company by 0.9% in the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after buying an additional 16 shares during the last quarter. Patton Albertson Miller Group LLC grew its position in Eli Lilly and Company by 2.8% in the 3rd quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after buying an additional 17 shares during the last quarter. Finally, Valley Wealth Managers Inc. grew its position in Eli Lilly and Company by 1.3% in the 3rd quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after buying an additional 17 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. BMO Capital Markets raised their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a report on Wednesday. Wells Fargo & Company raised their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Bank of America raised their target price on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, Morgan Stanley raised their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Trading Down 2.8 %

NYSE:LLY traded down $20.94 during trading hours on Friday, reaching $734.97. 4,535,213 shares of the company were exchanged, compared to its average volume of 3,087,178. The firm has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.57 and a beta of 0.37. The stock has a 50 day simple moving average of $761.75 and a 200 day simple moving average of $670.56. Eli Lilly and Company has a 52-week low of $419.80 and a 52-week high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The business had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the prior year, the firm posted $1.62 EPS. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. As a group, analysts predict that Eli Lilly and Company will post 13.49 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.